Skip to main content

Table 3 The diagnostic utility of the change in VAFmean or tumor makers

From: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

  

mRECIST

diagnostic ability PR/CR

PD

SD

PR/CR

specificity

sensitivity

PPV

NPV

VAFmean

increase

4

2

0

    

decrease

0

3

14

0.67

1.0

0.82

1.0

AFP (all cases)

increase

1

0

1

    

decrease

3

6

13

0.10

0.93

0.59

0.50

AFP (≥20 ng/mL at baseline)

increase

0

0

0

    

decrease

2

1

8

0

1.0

0.73

–

DCP (all cases)

increase

4

5

10

    

decrease

0

1

4

0.90

0.29

0.80

0.47

DCP (≥40mAU/mL at baseline)

increase

4

4

6

    

decrease

0

1

3

0.89

0.33

0.75

0.47

  1. mRECIST modified Response Evaluation Criteria in Solid Tumors, AFP α-fetoprotein, DCP des-gamma-carboxy pro-thrombin, VAF variant allele frequency, PD progressve disease, SD stable disease, PR partial response, CR complete response, PPV positive predictive value, NPV negative predictive value
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us